Alliance A041702: A randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (≥ 70 years of age) with chronic lymphocytic leukemia (CLL)
- Citation:
- Blood vol 134 (Supplement 1) abstr 642 CLL
- Meeting Instance:
- ASH 2019
- Year:
- 2019
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Leukemia
- Sec. Committees:
- Older Adult
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA189823, U24CA196171; U10CA180820, UG1CA232760 (ECOG-ACRIN)
- Corr. Author:
- Authors:
- Jennifer A. Woyach Amy S. Ruppert Gabriela Perez Allison Booth Diane Feldman Elie Dib Aminah Jatoi Jennifer Le-Rademacher Nyla Heerema Gerard Lozanski Richard Little Wei Ding Richard Stone Sumithra Mandrekar John C Byrd
- Networks:
- LAPS-MA036, LAPS-MN026, LAPS-OH007, MCRC, OH070
- Study
- Alliance-A041702
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: